Toggle navigation EN

Publikationen 2016

  1. Sisignano M, Parnham MJ, and Geisslinger G. Drug repurposing for the development of novel analgesics. Trends Pharmacol Sci 2016 Mar;37(3):172-83
  2. Lötsch J and Ultsch A. A computational functional genomics based self-limiting self-concentration mechanism of cell specialization as a biological role of jumping genes. Integrative Biology 2016 Jan;8(1):91-103
  3. Walter C, Knothe C, and Lötsch J. Abuse-deterrent opioid formulations: Pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016 Jul;55(7):751-67
  4. Tafferner N, Barthelmes J, Eberle M, Ulshöfer T, Henke M, deBruin N, Mayer CA, Foerch C, Geisslinger G, Parnham MJ, and Schiffmann S. Alpha-methylacyl-CoA racemase deletion has mutually counteracting effects on T-cell responses, associated with unchanged course of EAE. Eur J Immunol 2016 Mar;46(3):570-81
  5. Grimm M, Tischner D, Troidl K, Juárez JA, Sivaraj KK, Ferreirós N, Geisslinger G, Binder CJ, and Wettschureck N. S1P2/G12/13 Signaling Negatively Regulates Macrophage Activation and Indirectly Shapes the Atheroprotective B1-Cell Population. Arterioscler Thromb Vasc Biol  2016 Jan;36(1):37-48
  6. Blöcher R, Lamers C, Wittmann SK, Merk DP, Hartmann M, Weizel L, Diehl O, Brüggerhof A, Boß M, Kaiser A, Schader T, Göbel T, Grundmann M, Angioni C, Heering J, Geisslinger G, Wurglics M, Kostenis E, Brüne B, Steinhilber D, Schubert-Zsilavecz M, Kahnt AS, and Proschak E. N-Benzylbenzamides: a novel merged scaffold for orally available dual soluble epoxide hydrolase / peroxisome proliferator-activated receptor γ modulators.  Med Chem 2016 Jan 14;59(1):61-81
  7. Lötsch J, Ultsch A, and Hummel T. How many and which odor identification items are needed to establish normal olfactory function? Chem Sens 2016 May;41(4):339-44
  8. Lötsch J, Ultsch A, Eckhardt M, Huart C, Rombaux P, and Hummel T. Brain lesion-pattern analysis in patients with olfactory dysfunctions following head trauma. Neuroimage: Clin 11, 2016, 99–105
  9. Lötsch J and Ultsch A. Process pharmacology: A pharmacological data science approach to drug development and therapy. CPT Pharmacometrics Syst Pharmacol 2016 Apr;5(4):192-200
  10. Dimova V, Oertel BG, and Lötsch J. Using a standardized clinical quantitative sensory testing battery to judge the clinical relevance of sensory differences between adjacent body areas. Clin J Pain 2016 Jun 13. [Epub ahead of print]
  11. Zschiebsch K, Fischer C, Pickert G, Häussler A, Radeke H, Grösch S, Ferreirós N, Geisslinger G, Werner ER, and Tegeder I. Tetrahydrobiopterin attenuates DSS-evoked colitis in mice by rebalancing redox and lipid signaling. J Crohns Colitis 2016 Aug;10(8):965-78
  12. Möser CV, Meissner M, Laarmann K, Olbrich K, King-Himmelreich TS, Wolters MC, Geisslinger G, and Niederberger E. The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model. Biochem Pharmacol 2016 Mar 1;103:64-73
  13. de Bruin NM, Schmitz K, Schiffmann S, Tafferner N, Schmidt M, Jordan H, Häußler A, Tegeder I, Geisslinger G, and Parnham MJ. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis. Behav Brain Res 2016 Mar 1;300:160-74
  14. Hanke T, Merk D, Steinhilber D, Geisslinger G, and Schubert-Zsilavecz M. Small molecules with anti-inflammatory properties in clinical development. Pharmacol Ther 2016 Jan;157:163-87
  15. Willems LM, Zahn N, Ferreirós N, Scholich K, Maggio N, Deller T, and Vlachos A. Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy. Acta Neuropathol Commun 2016 Mar 31;4(1):28
  16. Lötsch J, Hähner A, Goßrau G, Hummel C, Walter C, Ultsch A, and Hummel T. Smell of pain: Intersection of nociception and olfaction. Pain 2016 Oct;157(10):2152-7
  17. Kringel D, Ultsch A, Zimmermann M, Jansen JP, Ilias W, Freynhagen R, Griessinger N, Kopf A, Stein C, Doehring A, Resch E, and Lötsch J. Emergent biomarker derived from next generation sequencing to identify pain patients requiring uncommonly high opioid doses. Pharmacogenomics J 2016 May 3. doi: 10.1038/tpj.2016.28. [Epub ahead of print]
  18. Knothe C, Shiratori H, Resch E, Ultsch A, Geisslinger G, Doehring A, and Lötsch J. Disagreement between two common biomarkers of global DNA methylation. Clin Epigenet 2016 May 23;8:60. doi: 10.1186/s13148-016-0227-0. eCollection 2016
  19. Lötsch J, Ultsch A, and Hummel T. A unifying data driven model of human olfactory pathology representing known etiologies of dysfunction. Chem Senses 2016 Aug 26. pii: bjw089. [Epub ahead of print]
  20. Muth C, Harder S, Uhlmann L, Rochon J, Fullerton B, Güthlin C, Erler A, Beyer M, vanden Akker M, Perera R, Knottnerus A, Martinez JV, Gerlach FM, and Haefeli W. Pilot study to test the feasibility of a trial design and complex intervention on PRIoritising MUltimedication in Multimorbidity in general practices (PRIMUMpilot). BMJ open 2016 Jul 25;6(7):e011613
  21. Olbrich K, Costard L, Möser CV, Syhr KM, King-Himmelreich TS, Wolters MC, Schmidtko A, Geisslinger G, and Niederberger E. Cleavage of SNAP-25 ameliorates cancer pain in a mouse model of melanoma. Eur J Pain 2016 Jun 15. doi: 10.1002/ejp.904. [Epub ahead of print]
  22. Barthelmes J, Tafferner N, Kurz J, de Bruin N, Parnham MJ, Geisslinger G, and Schiffmann S. Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues. J Vis Exp 2016 May 8;(111)
  23. Wegner MS, Schiffmann S, Parnham MJ, Geisslinger G, and Grösch S. The enigma of ceramide synthase regulation in mammalian cells. Prog Lipid Res 2016 May 13;63:93-119
  24. Josipovic I, Fork C, Preussner J, Prior KK, Iloska D, Vasconez AE, Labocha S, Angioni C, Thomas D, Ferreirós N, Looso M, Pullamsetti SS, Geisslinger G, Steinhilber D, Brandes RP, and Leisegang MS. PAFAH1B1 and the lncRNA NONHSAT073641 maintain an angiogenic phenotype in human endothelial cells. Acta Physiol (Oxf) 2016 Apr 28
  25. King-Himmelreich TS, Schramm S, Wolters MC, Schmetzer J, Möser CV, Knothe C, Resch E, Peil J, Geisslinger G, and Niederberger E. The impact of endurance exercise on global and AMPK gene-specific DNA methylation. Biochem Biophys Res Commun 2016 May 27;474(2):284-90
  26. Henke N, Ferreirós N, Geisslinger G, Ding MG, Essler S, Fuhrmann DC, Geis T, Namgaladze D, Dehne N, and Brüne B. Loss of HIF-1α in macrophages attenuates AhR/ARNT-mediated tumorigenesis in a PAH-driven tumor model. Oncotarget 2016 May 3;7(18):25915-29
  27. Ultsch A, Kringel D, Kalso E, Mogil JS, and Lötsch J. A data science approach to candidate gene selection of pain regarded as a process of learning and neural plasticity. Pain 2016 Aug 19. [Epub ahead of print]
  28. Lötsch J and Ultsch A. A machine-learned computational functional-genomics based approach to drug classification. Eur J Clin Pharmacol 2016 Oct 1
  29. Knothe C, Oertel BG, Ultsch A, Kettner M, Schmidt PH, Wunder C, Toennes SW, Geisslinger G, and Lötsch J. Pharmacoepigenetics of the role of DNA methylation in µ-opioid receptor expression in different human brain regions. Epigenomics 2016 Sep 29. [Epub ahead of print]
  30. Lötsch J, Hummel T, and Ultsch A. Machine-learned pattern identification in olfactory subtest results. Nat Sci Rep 2016 Oct 20;6:35688
  31. Shiratori H, Feinweber C, Knothe C, Lötsch J, Geisslinger G, Parnham M, and Resch E. High-throughput analysis of global DNA methylation using methyl-sensitive digestion. PLoS One 2016 Oct 17;11(10):e0163184
  32. Kringel D and Lötsch J. Next-generation sequencing of human opioid receptor genes based on a custom AmpliSeq™ library and Ion Torrent personal genome machine. Clin Chim Acta 2016 Oct 8;463:32-38
  33. Sisignano M, Angioni C, Park CK, Meyer Dos Santos S, Jordan H, Kuzikov, M, Liu D, Zinn S, Hohmann SW, Schreiber Y, Zimmer B, Schmidt M, Lu R, Suo J, Zhang DD, Schäfer SMG, Hofmann M, Yekkirala AS, DeBruin N, Parnham MJ, Woolf CJ, Ji RR, Scholich K, and Geisslinger G. Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. Proc Natl Acad Sci USA 2016 Nov 1;113(44):12544-12549
  34. Willems LM, Zahn N, Ferreirós N, Scholich K, Maggio N, Deller T, Vlachos A. Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy. Acta Neuropathol Commun 2016 Mar 31;4:28. doi: 10.1186/s40478-016-0303-x
  35. Bender C, Christen S, Scholich K, Bayer M, Pfeilschifter JM, Hintermann E, Christen U. Islet-expressed CXCL10 Promotes Autoimmune Destruction of Islet Iso-Grafts in Mice with Type 1 Diabetes. Diabetes 2016 Oct 26. pii: db160547
  36. Pierre S, Linke B, Suo J, Tarighi N, DelTurco D, Thomas D, Ferreiros N, Stegner D, Frölich S, Sisignano M, Meyer Dos Santos S, DeBruin N, Nüsing RM, Deller T, Nieswandt B, Geisslinger G, and Scholich K. GPVI and thromboxane receptor on platelets promote proinflammatory macrophage phenotypes during cutaneous inflammation. J Invest Dermatology (in press)
  37. Treutlein EM, Zinn S, and Scholich K,  NSAIDS in the light of fever, inflammation and pain. Pharmakon (in press)
  38. Grösch S, Niederberger E, and Geisslinger G. Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain. Expert Opin Investig Drugs 2016 Nov 20:1-11 [Epub ahead of print]
  39. Maucher IV, Rühl M, Kretschmer SB, Hofmann B, Kühn B, Fettel J, Vogel A, Flügel KT, Manolikakes G, Hellmuth N, Häfner AK, Golghalyani V, Ball AK, Piesche M, Matrone C, Geisslinger G, Parnham MJ, Karas M, Steinhilber D, Roos J, and Maier TJ. Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418. Biochem Pharmacol 2016 Nov 4 [Epub ahead of print]
  40. Pierre S, Linke B, Jing S, Tarighi N, Del Turco D, Thomas D, Ferreiros N, Stegner D, Frölich S, Sisignano M, Meyer Dos Santos S, deBruin N, Nüsing RM, Deller T, Nieswandt B, Geisslinger G, and Scholich K. GPVI and thromboxane receptor on platelets promote proinflammatory macrophage phenotypes during cutaneous inflammation. J Invest Dermatol 2016 Nov 3
  41. Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E,  Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, and Cinatl Jr. J (2016) SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med 2016 (in press).
  42. Tunaru S, Chennupati R, Nüsing RM, and Offermanns S. Arachidonic Acid Metabolite 19(S)-HETE Induces Vasorelaxation and Platelet Inhibition by Activating Prostacyclin (IP) Receptor. PLoS One 2016 Sep 11(9):e0163633
  43. Slattery P, Frölich S, Schreiber Y, and Nüsing RM. COX-2 gene dosage-dependent defects in kidney development. Am J Physiol Renal Physiol 2016 May 310:F1113-22
  44. Siegmund SV, Wojtalla A, Schlosser M, Schildberg FA, Knolle PA, Nüsing RM, Zimmer A, Strassburg CP, and Singer MV. Cyclooxygenase-2 contributes to the selective induction of cell death by the endocannabinoid 2-arachidonoyl glycerol in hepatic stellate cells. Biochem Biophys Res Commun 2016 Feb 470:678-84
  45. Wobst I, Ebert L, Birod K, Wegner MS, Hoffmann M, Thomas D, Angioni C, Parnham MJ, Steinhilber D, Tegeder I, Geisslinger G, and Grösch S. R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4. Int J Mol Sci 2016 Dec 30;18(1)